Glycative stress from advanced glycation end products (AGEs) and dicarbonyls: An emerging biological factor in cancer onset and progression

Molecular Nutrition & Food Research
Jer-An LinGow-Chin Yen

Abstract

In recent years, glycative stress from exogenous or endogenous advanced glycation end products (AGEs) and highly reactive dicarbonyls has gained great attention for its putative effects on cancer development. AGEs are a group of compounds formed from the complex chemical reaction of reducing sugars with compounds containing an amino group. AGEs bind to and activate the receptor for AGEs (RAGE), which is a predominant modulator of inflammation-associated cancer, and AGEs induce reactive oxygen species that are an important regulator of the hallmarks of cancer. Dicarbonyls, which are formed during glycolysis, lipid oxidation, or protein degradation, include glyoxal, methylglyoxal, and 3-deoxyglucosone and are regarded as major precursors of AGEs. These dicarbonyls not only fuel the AGE pool in living organisms but also evoke carbonyl stress, which may contribute to the carbonylative damage of carbohydrates, lipids, proteins, or DNA. Carbonylative damage then leads to many lesions, some of which are implicated in the pathogenesis of cancer. In this review, studies regarding the effects of AGEs and dicarbonyls on cancer onset or progression are systematically discussed, and the utilization of AGE inhibitors and dicarbonyl scavenger...Continue Reading

References

Apr 8, 1992·Biochimica Et Biophysica Acta·M A van BoekelH J Hoenders
Feb 20, 1991·International Journal of Cancer. Journal International Du Cancer·M RayS Ray
Apr 28, 1986·The American Journal of Medicine·E C KuD W Scholer
Jul 1, 1966·Proceedings of the National Academy of Sciences of the United States of America·L G Együd, A Szent-Györgyi
Jun 7, 1968·Science·L G Együd, A Szent-Györgyi
Sep 15, 1995·International Journal of Cancer. Journal International Du Cancer·M TakahashiN Taniguchi
Mar 16, 1993·European Journal of Pharmacology·T P MiskoM G Currie
Oct 29, 1993·Biochemical and Biophysical Research Communications·S MikiT Kishimoto
May 28, 1993·International Journal of Cancer. Journal International Du Cancer·J HalderS Ray
Aug 5, 1996·Biochemical and Biophysical Research Communications·A OkadoN Taniguchi
Jul 14, 2000·Physiological Reviews·M Wyss, R Kaddurah-Daouk
Mar 29, 2001·Diabetologia·R SinghL Beilin
Nov 9, 2001·Biochemical and Biophysical Research Communications·H ZillV Faist
Feb 21, 2002·Biochemical Pharmacology·Georg T WondrakMyron K Jacobson
Apr 18, 2002·Leukemia·J B Almond, G M Cohen
Dec 31, 2002·Biochemical and Biophysical Research Communications·Holger ZillVeronika Faist
Jan 9, 2003·Mutation Research·Michael J RobertsElaine L Jacobson
Mar 18, 2003·International Journal of Cancer. Journal International Du Cancer·Hiroki KuniyasuHideaki Kondo
Oct 22, 2003·Archives of Biochemistry and Biophysics·Samuel Rahbar, James L Figarola
Oct 29, 2003·Toxicology Letters·Jung Hoon Kang
Mar 11, 2004·The Journal of Investigative Dermatology·Riichiro AbeHiroshi Shimizu
May 28, 2004·Acta Oncologica·Henriette LindbergTorben Skovsgaard
Sep 8, 2004·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·T IchinoseT Shibamoto
Jun 21, 2005·Annals of the New York Academy of Sciences·Wen-Hsiung ChanYan-Der Hsuuw
Jul 23, 2005·Annals of the New York Academy of Sciences·Paul J Thornalley
Jul 23, 2005·Annals of the New York Academy of Sciences·Hyon Jae LeePaul J Beisswenger
Jul 23, 2005·Annals of the New York Academy of Sciences·Helen Vlassara
Jul 23, 2005·Annals of the New York Academy of Sciences·Jeroen W J van HeijstCasper G Schalkwijk
Oct 8, 2005·The Journal of Pharmacology and Experimental Therapeutics·Georg T WondrakElaine L Jacobson
Nov 2, 2005·Journal of Cancer Research and Clinical Oncology·Hai-Yan SongZhao-You Tang
Jan 28, 2006·Cell·Ravichandran RamasamyAnn Marie Schmidt
May 23, 2006·Current Molecular Medicine·Takashi SatoMasayoshi Takeuchi
May 26, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Xuming JiaLingyun Wu
May 30, 2006·Diabetes Care·Amy G HuebschmannJane E B Reusch
Nov 15, 2006·Molecular Nutrition & Food Research·Chih-Yu LoChi-Tang Ho

❮ Previous
Next ❯

Citations

Jan 24, 2017·Cancer Letters·Christina PiperiAthanasios G Papavassiliou
Jan 29, 2017·Molecular Nutrition & Food Research·Ludmilla BärMichael Föller
Sep 21, 2018·PloS One·Katarzyna Zabłocka-SłowińskaHalina Grajeta
Sep 25, 2018·Current Diabetes Reviews·Rabia NabiMohammad Salman Khan
Mar 21, 2020·Endocrinology·Juan H Vasquez, Jeremy C Borniger
Sep 19, 2017·Biochemistry. Biokhimii︠a︡·M V Sudnitsyna, N B Gusev
Jun 16, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Wenzhe YuMingfu Wang
Sep 16, 2017·Journal of Food and Drug Analysis·Wan-Ju YehChi-Hao Wu
May 27, 2017·Seminars in Cancer Biology·Mohammad Imran KhanHasan Mukhtar
Apr 20, 2021·Frontiers in Oncology·Alessia LeoneClaudia Miele
Jul 3, 2021·Cancers·Diren Beyoğlu, Jeffrey R Idle
Aug 12, 2021·Comprehensive Reviews in Food Science and Food Safety·Gengjun Chen
Feb 10, 2018·Journal of Agricultural and Food Chemistry·Jer-An LinGow-Chin Yen
Nov 3, 2021·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Catrin HerpichJana Raupbach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.